Calporta Therapeutics (Series A)

Funding Details
Awarder
Inbox
Date Award
June 15, 2015
Vertical
Biotechnology
Funding URL
View Funding Page
Funding Amount:
$10,000,000
Company Info
Company Description
Calporta is developing selective small molecule agonists of TRPML1 for the treatment of Niemann-Pick C Disease (NPC) and other lysosomal storage diseases. Agonists of TRPML1 restore calcium efflux and normalize lysosomal trafficking and function.
Market
Lysosomal storage diseases
Location
La Jolla, California, USA
Coinvestors
Avalon Ventures, GlaxoSmithKline
Links
Back to Home Back to Biotechnology Deals View Funding Announcement